CSPC Pharmaceutical Group Limited (CSPCY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CSPC Pharmaceutical Group Limited (CSPCY) trades at $4.19 with AI Score 48/100 (Grade C). CSPC Pharmaceutical Group Limited is a leading Chinese pharmaceutical company engaged in the research, development, manufacturing, and distribution of a wide array of pharmaceutical products. Market cap: $12.07B, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for CSPCY: CSPCY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CSPCY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CSPCY: the 1 perspectives are evenly split.
How is this calculated? →CSPC Pharmaceutical Group Limited (CSPCY) Healthcare & Pipeline Overview
CSPC Pharmaceutical Group Limited stands as a prominent player in the global pharmaceutical landscape, offering a diverse range of medications across multiple therapeutic areas, including oncology, cardiovascular health, and pain management, backed by robust research and development capabilities.
What Is the Investment Thesis for CSPCY?
CSPC Pharmaceutical Group Limited presents a strong investment thesis driven by its robust product portfolio and strategic market positioning. With a market capitalization of $12.07B and a P/E ratio of 18.7, the company demonstrates solid profitability, evidenced by a profit margin of 14.9% and a gross margin of 65.6%. Key growth catalysts include the expansion of its oncology product line, particularly Duomeisu and Keaili, which are gaining traction in both domestic and international markets. Additionally, CSPC's commitment to research and development, with significant investments aimed at enhancing its pharmaceutical offerings, positions the company favorably for future growth. The ongoing demand for innovative healthcare solutions, particularly in the Asia-Pacific region, further supports CSPC's growth trajectory. However, investors should remain aware of potential risks, including regulatory challenges and competitive pressures from both domestic and international players.
Based on FMP financials and quantitative analysis
CSPCY Key Highlights
- Market Cap of $12.07B reflects CSPC's strong market presence and growth potential.
- P/E ratio of 18.7 indicates a competitive valuation relative to industry peers.
- Profit margin of 14.9% showcases effective cost management and operational efficiency.
- Gross margin of 65.6% exceeds industry averages, highlighting CSPC's pricing power and product quality.
- Dividend yield of 3.31% provides a steady income stream for investors.
Who Are CSPCY's Competitors?
CSPCY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BIOVF Swedish Orphan Biovitrum AB (publ) | $47.35 | -1.35% | $16.38B | 56 |
| ERFSF Eurofins Scientific SE | $78.98 | -1.53% | $13.67B | 43 |
| RCDTF Recordati Industria Chimica e Farmaceutica S.p.A. | $58.00 | +0.00% | $11.80B | 54 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.66B | 63 |
| BDUUF Bangkok Dusit Medical Services Public Company Limited | $0.60 | -6.25% | $9.54B | 52 |
| ORINY Orion Oyj | $38.86 | +0.00% | $21.87B | 64 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 64 |
| GSK GSK plc | $53.09 | -1.06% | 107B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CSPCY's Key Strengths?
- Strong market presence in China and expanding international operations.
- Diverse product portfolio addressing multiple therapeutic areas.
- Robust research and development capabilities driving innovation.
- High gross margin indicating effective cost management.
What Are CSPCY's Weaknesses?
- Dependence on the Chinese market for a significant portion of revenue.
- Potential regulatory challenges in international markets.
- Limited brand recognition outside of Asia compared to global competitors.
What Could Drive CSPCY Stock Higher?
- Expansion of oncology product line with new launches expected in 2026.
- Continued growth in the cardiovascular segment driven by increasing hypertension prevalence.
- Strategic partnerships aimed at enhancing international market penetration.
- Investment in R&D to foster innovation and product development.
- Regulatory approvals for new drugs anticipated in late 2026.
What Are the Key Risks for CSPCY?
- Regulatory challenges in international markets that may delay product launches.
- Competition from both domestic and international pharmaceutical companies impacting market share.
- Economic fluctuations affecting healthcare spending and demand for CSPC's products.
- Supply chain disruptions that could impact manufacturing and distribution.
What Are the Growth Opportunities for CSPCY?
- Expansion of Oncology Portfolio: CSPC's oncology segment, particularly its products Duomeisu and Keaili, is poised for significant growth due to rising cancer incidence rates and increasing healthcare expenditures. The global oncology market is expected to reach $300 billion by 2025, providing CSPC with a substantial opportunity to enhance its market share through innovative therapies and strategic partnerships.
- Development of Neurological Treatments: With a growing focus on neurological disorders, CSPC's products such as NBP and Enxi are positioned to address unmet medical needs in this area. The global market for neurological drugs is projected to grow at a CAGR of 5.1% from 2021 to 2028, driven by an aging population and increased awareness of neurological conditions.
- International Market Penetration: CSPC aims to expand its footprint in international markets, particularly in Europe and North America, where there is a high demand for quality pharmaceuticals. This strategic move is expected to enhance revenue streams and diversify its customer base, capitalizing on the global pharmaceutical market's projected growth.
- Investment in Research and Development: CSPC's commitment to R&D is a key growth driver, enabling the company to innovate and develop new products that meet evolving healthcare needs. With a focus on advanced drug delivery systems and personalized medicine, CSPC is well-positioned to lead in the rapidly changing pharmaceutical landscape.
- Functional Food and Healthcare Services: CSPC's diversification into functional food and healthcare services presents additional growth avenues. The global functional food market is expected to grow significantly, driven by consumer demand for health and wellness products, allowing CSPC to leverage its existing capabilities to capture market opportunities.
What Opportunities Does CSPCY Have?
- Expansion into international markets to diversify revenue streams.
- Growing demand for oncology and neurological treatments.
- Investment in R&D to develop innovative pharmaceutical solutions.
What Threats Does CSPCY Face?
- Intense competition from both domestic and international pharmaceutical companies.
- Regulatory changes that may impact product approvals and market access.
- Economic fluctuations affecting healthcare spending patterns.
What Are CSPCY's Competitive Advantages?
- Strong brand reputation built on quality and efficacy of pharmaceutical products.
- Robust research and development capabilities that drive innovation.
- Diverse product portfolio addressing a wide range of medical needs.
- Established distribution networks across Asia, the Americas, and Europe.
- Regulatory compliance and approvals that enhance credibility and market access.
What Does CSPCY Do?
CSPC Pharmaceutical Group Limited, established in 1992 and headquartered in Shijiazhuang, China, is a key player in the global pharmaceutical industry. The company has evolved significantly since its inception, transitioning from its original name, China Pharmaceutical Group Limited, to its current title in March 2013. CSPC is engaged in the research, development, manufacturing, and distribution of pharmaceutical products, with operations extending across the People's Republic of China, other Asian markets, the Americas, and Europe. The company's business is organized into three primary divisions: Finished Drugs, Bulk Products, and Functional Food and Others. CSPC's extensive portfolio includes treatments for neurological disorders, oncology, cardiovascular health, diabetes, and pain management, showcasing its commitment to addressing a wide spectrum of medical needs. Notable products include NBP for acute ischemic stroke, Duomeisu for various malignant tumors, Xuanning for hypertension, and Gubang for postmenopausal osteoporosis. In addition to finished pharmaceuticals, CSPC produces essential active pharmaceutical ingredients (APIs) and functional food items, further diversifying its offerings. The company's strategic focus on innovation and quality has positioned it as a leader in the pharmaceutical sector, with a strong commitment to research and development, ensuring its products meet the highest standards of efficacy and safety.
What Products and Services Does CSPCY Offer?
- Research, develop, and manufacture a wide range of pharmaceutical products.
- Offer treatments for various medical conditions, including oncology, cardiovascular health, and neurological disorders.
- Produce essential active pharmaceutical ingredients (APIs) for other pharmaceutical companies.
- Provide functional food products aimed at promoting health and wellness.
- Deliver healthcare services to enhance patient outcomes and support community health.
- Engage in global distribution of its products across multiple regions, including Asia, the Americas, and Europe.
How Does CSPCY Make Money?
- Generate revenue through the sale of finished pharmaceutical products across various therapeutic areas.
- Manufacture and supply active pharmaceutical ingredients (APIs) to other pharmaceutical companies.
- Offer functional food products that cater to health-conscious consumers.
- Provide healthcare services that complement its pharmaceutical offerings.
- Expand into international markets to diversify revenue streams and reduce dependence on domestic sales.
What Industry Does CSPCY Operate In?
CSPC Pharmaceutical Group Limited operates within the Drug Manufacturers - General industry, which is characterized by rapid innovation and increasing demand for pharmaceutical products globally. The global pharmaceutical market is projected to grow at a CAGR of approximately 6.3% from 2021 to 2028, driven by advancements in biotechnology, personalized medicine, and an aging population. CSPC's competitive landscape includes notable players such as Swedish Orphan Biovitrum AB (publ), Eurofins Scientific SE, Recordati Industria Chimica e Farmaceutica S.p.A., Orion Oyj, and Bangkok Dusit Medical Services Public Company Limited. CSPC's strong emphasis on research and development, combined with its extensive product portfolio, positions it well to capitalize on emerging market trends and consumer needs.
Who Are CSPCY's Key Customers?
- Hospitals and healthcare providers seeking effective pharmaceutical solutions.
- Pharmacies and drugstores distributing medications to consumers.
- Patients requiring treatments for various medical conditions.
- Healthcare institutions looking for reliable suppliers of active pharmaceutical ingredients.
- Consumers interested in functional food products for health and wellness.
Company Profile
CSPC Pharmaceutical Group Limited operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Shijiazhuang, CN. The company is led by CEO Lei Cai. CSPCY has traded publicly since 2021.
F-Score 5/9Financial Health
CSPC Pharmaceutical Group Limited's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 6.95 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE 11%Key Financial Metrics
Return on equity for CSPC Pharmaceutical Group Limited stands at 11.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.2%, showing how much profit it generates from its asset base. CSPCY trades at a trailing price-to-earnings ratio of 18.73, below the Healthcare sector average of ~23x. Its free cash flow yield is 5.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.19 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.5%, the inverse of the P/E and a quick read on earnings relative to price.
CSPCY Valuation & Market Position
With a $12.07B market cap, CSPC Pharmaceutical Group Limited sits in the large-cap segment of the market. Relative to its peer group, CSPCY's quantitative score of 48/100 is roughly in line with the peer average of 54/100.
FY2026 estForward Outlook
Wall Street analysts project CSPC Pharmaceutical Group Limited revenue of about $278.87B for fiscal 2026, with EPS near $0.00. The estimate reflects 21 contributing analysts.
CSPCY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in CSPC's future, indicating that executives believe the stock is undervalued.
- Community sentiment has shifted positively as discussions around innovative drug pipelines gain traction, highlighting potential growth areas.
- The pharmaceutical sector has seen increased demand due to ongoing health challenges, positioning CSPC to capitalize on this trend.
- Recent strategic partnerships in research and development have created optimism about the company's ability to expand its market presence.
Bear Case
- Concerns about regulatory hurdles in the pharmaceutical industry could impact CSPC's ability to bring new products to market.
- Negative sentiment from some investors stems from competitive pressures, as rivals are also advancing in similar therapeutic areas.
- Recent earnings reports have raised questions about profit margins, leading to skepticism about long-term sustainability.
- Market perception is cautious due to broader economic uncertainties, which may affect investor appetite for pharmaceutical stocks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CSPCY Latest News
-
The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight
Yahoo! Finance: CSPCY News · Jun 1, 2026
CSPCY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CSPCY.
Price Targets
Wall Street price target analysis for CSPCY.
CSPCY MoonshotScore
What does this score mean?
The MoonshotScore rates CSPCY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Lei Cai
CEO
Lei Cai has been instrumental in shaping CSPC Pharmaceutical Group Limited's strategic direction since his appointment as CEO. With a background in pharmaceuticals and extensive experience in management, he has overseen the company's growth and expansion into international markets. His leadership is characterized by a strong focus on innovation, quality, and operational excellence.
Track Record: Under Lei Cai's leadership, CSPC has achieved significant milestones, including the successful launch of several key products in oncology and neurology. His commitment to research and development has positioned the company as a leader in the pharmaceutical sector, driving both revenue growth and market share.
CSPC Pharmaceutical Group Limited ADR Information Unsponsored
An American Depositary Receipt (ADR) is a negotiable certificate issued by a U.S. bank representing shares in a foreign company's stock. CSPC Pharmaceutical Group Limited's ADR allows investors to trade shares on U.S. exchanges while holding a stake in the underlying company, facilitating access to international markets.
- Home Market Ticker: CSPC trades on the Hong Kong Stock Exchange under the ticker CSPC.
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: CSPC
CSPCY OTC Market Information
The OTC Other tier represents stocks that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. Companies in this tier may have less stringent reporting obligations, which can lead to less transparency and higher risks for investors compared to those listed on more regulated exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lower transparency and regulatory oversight compared to major exchanges.
- Potential for higher volatility due to limited trading volume.
- Increased risk of fraud or misrepresentation in financial reporting.
- Review CSPC's financial statements and earnings reports.
- Assess the company's competitive position and market trends.
- Investigate regulatory compliance and potential legal issues.
- Evaluate management's track record and strategic vision.
- Monitor market conditions and economic factors affecting the pharmaceutical industry.
- Established history and market presence since 1992.
- Strong product portfolio with multiple therapeutic areas.
- Commitment to research and development evidenced by new product launches.
CSPCY Healthcare Stock FAQ
What does CSPC Pharmaceutical Group Limited do?
CSPC Pharmaceutical Group Limited is engaged in the research, development, manufacturing, and distribution of pharmaceutical products. The company offers a diverse range of medications across various therapeutic areas, including oncology, cardiovascular health, and neurological disorders, serving markets in China, Asia, the Americas, and Europe.
What do analysts say about CSPCY stock?
Analysts generally view CSPC Pharmaceutical Group Limited as a solid player in the pharmaceutical sector, with a focus on growth driven by its diverse product portfolio and strategic market expansions. Key valuation metrics indicate a competitive position in the market, with a P/E ratio of 18.7 and a profit margin of 14.9%, reflecting effective operational management.
What are the main risks for CSPCY?
CSPC Pharmaceutical Group Limited faces several risks, including potential regulatory challenges that could impact product approvals and market access. Additionally, ongoing competition from both domestic and international pharmaceutical companies may affect its market share. Economic fluctuations could also influence healthcare spending patterns, impacting demand for CSPC's products.
What are the key factors to evaluate for CSPCY?
CSPC Pharmaceutical Group Limited (CSPCY) holds an AI score of 48/100 (low). P/E: 18.7x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does CSPCY data refresh on this page?
CSPCY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CSPCY's recent stock price performance?
CSPC Pharmaceutical Group Limited (CSPCY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market presence in China and expanding international operations. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CSPCY overvalued or undervalued right now?
CSPC Pharmaceutical Group Limited (CSPCY) trades at 18.7x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CSPCY?
Before investing in CSPC Pharmaceutical Group Limited (CSPCY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data sourced from company profiles and financial metrics.